Related Experiment Videos
[The use of Capoten in systemic scleroderma]
Terapevticheskii Arkhiv
|January 1, 1992
Summary
Captopril effectively manages sclerodermic renal crisis by stabilizing blood pressure and renal function. However, this study found no significant benefit of captopril for patients with Raynaud
Area of Science:
- Nephrology
- Rheumatology
- Clinical Pharmacology
Background:
- Sclerodermic renal crisis (SRC) is a severe complication of systemic sclerosis.
- Raynaud's syndrome is a common condition affecting blood circulation in extremities.
- Captopril, an angiotensin-converting enzyme inhibitor, is a potential treatment for these conditions.
Purpose of the Study:
- To evaluate the efficacy of captopril in patients with sclerodermic renal crisis.
- To assess the effectiveness of captopril in treating Raynaud's syndrome through a double-blind clinical trial.
Main Methods:
- Case series of 5 patients with SRC treated with long-term captopril (75-150 mg/day).
- Double-blind, placebo-controlled trial of captopril (37.5 mg/day for 2 weeks) in 16 patients with Raynaud's syndrome.
Main Results:
- Captopril demonstrated effectiveness in SRC patients, leading to decreased arterial pressure, reduced azotemia, alleviation of headaches, and stabilized renal function.
- No convincing evidence of captopril's beneficial effect on Raynaud's syndrome was observed in the clinical trial.
Conclusions:
- Long-term captopril therapy is effective for managing sclerodermic renal crisis.
- Captopril does not appear to be beneficial for Raynaud's syndrome.